Drugs / Celiprolol
Celiprolol
also known as
ACER-002 · ACER-002 FREE BASE · Celectol · Celiprol · Celiprolol hcl · CELIPROLOL HYDROCHLORIDE · Celiprolol pch · NSC-324509 · +1 more
Small molecule targets ADRB1, ADRB2 via inhibition / activation
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05432466 | Nov 2022 → Mar 2029 expected | Ehlers-Danlos syndrome, vascular type | Acer Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02380053 | Jun 2016 → Apr 2019 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00190411 | Oct 2003 → Apr 2011 | autosomal dominant Ehlers-Danlos syndrome, vascular type, chromosome 2q31.2 deletion syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03752931 Comparator | Dec 2018 → Dec 2019 | — | Abderrahmane Mami Hospital | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | celiprolol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00190411 ↗ |
| Known as | ACER-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | ACER-002 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | Celectol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | Celiprol | “receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.” NCT03752931 ↗ |
| Known as | Celiprolol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | CELIPROLOL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | Celiprolol pch | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | NSC-324509 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Known as | Selectol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27810 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor partial agonist” CHEMBL27810 ↗ |
| Action | Inhibit | “Celiprolol however is a unique beta-blocker which in addition to its beta-1-receptor blockade has partial beta-2-agonist activity” NCT02380053 ↗1“Beta-1 adrenergic receptor antagonist” CHEMBL27810 ↗ |
| Modality | Small molecule | — CHEMBL27810 ↗ |
| Route | Oral | “receiving 1 tablet per day of Celiprolol 200 mg in the morning” NCT03752931 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL27810 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor partial agonist” CHEMBL27810 ↗ |